Management of Locally Advanced Esophageal Cancer

被引：13

作者：

Zhou, Nicolas ^{[1
]}

Rajaram, Ravi ^{[1
]}

Hofstetter, Wayne L. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77005 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2020年 / 29卷 / 04期

关键词：

Esophageal cancer; Adenocarcinoma; Squamous cell carcinoma; Chemoradiation; Salvage; MSI; PD-L1; HER2; GASTROESOPHAGEAL JUNCTION CANCER; MINIMALLY INVASIVE ESOPHAGECTOMY; LIMITED TRANSHIATAL RESECTION; ENDOSCOPIC VACUUM THERAPY; SQUAMOUS-CELL CARCINOMA; QUALITY-OF-LIFE; GENE AMPLIFICATION; PERIOPERATIVE CHEMOTHERAPY; SALVAGE ESOPHAGECTOMY; NEOADJUVANT CHEMORADIOTHERAPY;

D O I：

10.1016/j.soc.2020.06.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Management of locally advanced esophageal cancer is evolving. Trimodality therapy with chemoradiation followed by surgical resection has become the standard of care. However, the value of planned surgery after response to therapy is in question. In this article, we discuss the current practice principles and evidence for the treatment of locally advanced esophageal cancer. Topics will include various neoadjuvant therapies, trimodality versus bimodality therapy, and outcomes for salvage esophagectomies. In addition, emerging novel therapies, such as HER2 inhibitors and immunotherapy, are available for unresectable or metastatic disease, enabling a greater armamentarium of tumor biology-specific treatments. © 2020 Elsevier Inc.

引用

页码：631 / 646

页数：16

共 89 条

[1] Use of esophageal stents to relieve dysphagia during neoadjuvant therapy prior to esophageal resection: a systematic review [J].

Ahmed, O. ;

Bolger, J. C. ;

O'Neill, B. ;

Robb, W. B. .

DISEASES OF THE ESOPHAGUS, 2020, 33 (01)

[2] Esophageal and Esophagogastric Junction Cancers, Version 2.2019 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Bentrem, David J. ;

Chao, Joseph ;

Corvera, Carlos ;

Das, Prajnan ;

Denlinger, Crystal S. ;

Enzinger, Peter C. ;

Fanta, Paul ;

Farjah, Farhood ;

Gerdes, Hans ;

Gibson, Michael ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Johung, Kimberly L. ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Leong, Stephen ;

Ly, Quan P. ;

Matkowskyj, Kristina A. ;

McNamara, Michael ;

Mulcahy, Mary F. ;

Paluri, Ravi K. ;

Park, Haeseong ;

Perry, Kyle A. ;

Pimiento, Jose ;

Poultsides, George A. ;

Roses, Robert ;

Strong, Vivian E. ;

Wiesner, Georgia ;

Willett, Christopher G. ;

Wright, Cameron D. ;

McMillian, Nicole R. ;

Pluchino, Lenora A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (07) :855-883

[3] Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer [J].

Allum, William H. ;

Stenning, Sally P. ;

Bancewicz, John ;

Clark, Peter I. ;

Langley, Ruth E. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5062-5067

[4]

[Anonymous], 2019, ESOPHAGEAL ESOPHAGOG

[5]

[Anonymous], 2019, J CLIN ONCOL S

[6] Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus [J].

Atay, Scott M. ;

Correa, Arlene ;

Hofstetter, Wayne L. ;

Swisher, Stephen G. ;

Ajani, Jaffer ;

Altorki, Nassar K. ;

Blackmon, Shanda H. ;

Blackstone, Eugene H. ;

Rice, Thomas W. ;

Crabtree, Traves D. ;

D'Amico, Thomas A. ;

Darling, Gail E. ;

DeMeester, Steven R. ;

DeMeester, Thomas R. ;

Worrell, Stephanie G. ;

Ferri, Lorenzo E. ;

Gaissert, Henning A. ;

Krasna, Mark J. ;

Lerut, Antoon ;

Nafteux, Phillippe ;

Moons, Johnny ;

Little, Alex G. ;

Low, Donald E. ;

Carrott, Phillip W. ;

Schmidt, Henner M. ;

Miller, Daniel ;

Nason, Katie S. ;

Luketich, James D. ;

Orringer, Mark B. ;

Chang, Andrew C. ;

Rizk, Nabil P. ;

Salo, Jarmo A. ;

Schneider, Paul M. ;

Smithers, Bernard Mark ;

Vallboehmer, Daniel ;

van Lanschot, J. J. ;

Varghese, Thomas K. ;

Watson, Thomas J. ;

Peters, Jeff H. ;

Yang, Stephen C. .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 157 (03) :1264-+

[7]

Bancewicz J, 2002, LANCET, V359, P1727

[8] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [J].

Bang, Y. -J. ;

Ruiz, E. Yanez ;

Van Cutsem, E. ;

Lee, K. -W. ;

Wyrwicz, L. ;

Schenker, M. ;

Alsina, M. ;

Ryu, M. -H. ;

Chung, H. -C. ;

Evesque, L. ;

Al-Batran, S. -E. ;

Park, S. H. ;

Lichinitser, M. ;

Boku, N. ;

Moehler, M. H. ;

Hong, J. ;

Xiong, H. ;

Hallwachs, R. ;

Conti, I. ;

Taieb, J. .

ANNALS OF ONCOLOGY, 2018, 29 (10) :2052-2060

[9] Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma [J].

Barbetta, Arianna ;

Hsu, Meier ;

Tan, Kay See ;

Stefanova, Dessislava ;

Herman, Koby ;

Adusumilli, Prasad S. ;

Bains, Manjit S. ;

Bott, Matthew J. ;

Isbell, James M. ;

Janjigian, Yelena Y. ;

Ku, Geoffrey Y. ;

Park, Bernard J. ;

Wu, Abraham J. ;

Jones, David R. ;

Molena, Daniela .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06) :2710-2719

[10]

Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118

← 1 2 3 4 5 6 7 8 9 →